Table 3 Treatment response of SR-aGVHD between the two groups at week 4

CR rates of aGVHD grade, n/n (%)

 II-IV

54/65 (83.1%)

36/65 (55.4%)

0.001

 III-IV

26/33 (78.9%)

11/33 (36.4%)

< 0.001

ORR of aGVHD grade, n/n (%)

 II-IV

61/65 (93.8%)

55/65 (84.6%)

0.09

 III-IV

29/33 (87.9%)

25/33 (75.8%)

0.202

CR rates of aGVHD involved organs, n/n (%)

 Skin

46/55 (83.6%)

28/53 (52.8%)

0.001

 GI

33/42 (78.6%)

22/48 (45.8%)

0.001

 Liver

9/15 (60%)

3/17 (17.6%)

0.014

ORR of aGVHD according to involved organs, n/n (%)

 Skin

52/55 (94.5%)

45/53 (84.9%)

0.098

 GI

39/42 (92.9%)

38/48 (79.2%)

0.065

 Liver

11/15 (73.3%)

10/17 (58.8%)

0.388

CR rate of aGVHD involved ≥ 2 organs, n/n (%)

29/37 (78.4%)

15/37 (40.5%)

0.001

ORR of aGVHD involved ≥ 2 organs, n/n (%)

34/37 (91.9%)

28/37 (75.7%)

0.058